A Phase Ib/II study of ilixadencel in combination with checkpoint inhibitors (CPIs) for head & neck cancer, gastric adenocarcinoma and non-small cell lung cancer
Phase of Trial: Phase I/II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Ilixadencel (Primary)
- Indications Gastric cancer; Head and neck cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Apr 2018 New trial record
- 03 Apr 2018 According to an Immunicum media release, the Company plans to enroll the first patient during the second half of 2018.
- 03 Apr 2018 According to an Immunicum media release, the study protocol is now in its final stages expects to submit the trial documentation first to the US Food and Drug Administration, followed by submission for ethical review, during the second quarter 2018.